What is Alterome?
Alterome Therapeutics is a clinical-stage biotechnology firm dedicated to developing precise therapies for cancer patients. Employing a structure-guided drug discovery methodology, the company focuses on creating targeted oncology treatments for high-value oncogenic drivers that currently have limited therapeutic options. Their pipeline includes innovative small molecules designed to address challenging targets such as AKT and KRAS, reflecting a strong commitment to scientific advancement and improving patient outcomes.
How much funding has Alterome raised?
Alterome has raised a total of $132M across 1 funding round:
Series B
$132M
Series B (2024): $132M, investors not publicly disclosed
What's next for Alterome?
The substantial enterprise-level capital infusion positions Alterome Therapeutics for accelerated growth and the advancement of its promising drug candidates through clinical trials. This strategic backing is expected to fuel further research and development, particularly in their first-in-class small molecule programs targeting AKT and KRAS. The company's focus on difficult-to-treat cancers suggests a long-term strategy aimed at capturing significant market share in areas with unmet medical needs, potentially leading to transformative treatments for cancer patients.
See full Alterome company page
